Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

What was studied

This phase 1-2 trial tested daraxonrasib, or RMC-6236, in advanced lung cancer with RAS mutations. The cancer was non-small-cell lung cancer, or NSCLC. People had had earlier treatment. Daraxonrasib is an oral drug. Doses ranged from 10 to 400 mg once daily in 21-day cycles. The main aim was safety. Others were response and how long it lasts. The data cutoff was July 21, 2025. By then, 136 people on 300 mg or less could be assessed.

What they found

Side effects of any grade were reported in 99. Rash, diarrhea, nausea and vomiting were common. So were mucositis or stomatitis. Each occurred in at least 30. Grade 3 or higher side effects occurred in 54. Pneumonia occurred in 10 and diarrhea in 9. Rash occurred in 8 and anemia in 5. Grade 5 side effects also occurred. Response was seen in 31 at 120 mg or less. It was 34 at 160 to 220 mg. It was 37 at 300 mg. All figures are shares of people.

What it means for patients

The authors report that side effects of grade 3 or higher occurred in 54. They report antitumor activity in more than 30. These are shares of people on 300 mg or less.

Why it is not certain yet

This was an early-phase trial. The abstract does not describe a comparison group. Side effects were common. Many were of grade 3 or higher. The company Revolution Medicines funded the trial.

Source

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

We restate facts from the source record in our own words. The original wording belongs to its publisher.